BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting02-03-2022
02-03-2022
Post Viatris deal, eyes on execution for Biocon
Analysts said if Biocon manages to direct business growth in the right manner, it could be a game changer01-03-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
Biocon Biologics to acquire Viatris' Biosimilars Business.28-02-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Acquisition
Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash.28-02-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meetings17-02-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting15-02-2022
Rahul Bajaj Passes Away: Corporates, Political Leaders Express Grief
Executive chairperson of Biocon, Kiran Majumdar Shaw, a close friend of the late industrialist, said that she was "devastated" at Mr Bajaj's death12-02-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement for transfer of equity shares to IEPF Authority08-02-2022
Biocon gains 3%, at 6-month high in a weak market; stock up 18% in 3 weeks
Biocon said its subsidiary Biocon Pharma has received approval of its ANDA for Posaconazole Delayed-Release tablets from the US FDA.08-02-2022